Abciximab
Drug Info:
Top
Abciximab
Brand names: ReoPro®
- Espa�ol:
- Abciximab Solución para inyección
Abciximab Solution for injection
What is this medicine?
ABCIXIMAB (ab SIX i mab) prevents blood clots during episodes of chest pain or a heart attack. It may be used during heart surgery.
This medicine may be used for other purposes; ask your health care provider or pharmacist if you have questions.
What should I tell my health care provider before I take this medicine?
They need to know if you have any of these conditions:
•bleeding problems or blood disorders
•brain tumor or aneurysm
•high blood pressure
•previous stroke
•recent injury or surgery
•took a drug to prevent blood clots like warfarin in the past week
•vasculitis
•an unusual or allergic reaction to abciximab, mouse or human proteins, other medicines, foods, dyes, or preservatives
•pregnant or trying to get pregnant
•breast-feeding
How should I use this medicine?
The medicine is for injection or infusion into a vein. It is given by a health care professional in a hospital or clinic setting.
Talk to your pediatrician regarding the use of this medicine in children. Special care may be needed.
Overdosage: If you think you have taken too much of this medicine contact a poison control center or emergency room at once.
NOTE: This medicine is only for you. Do not share this medicine with others.
What may interact with this medicine?
•aspirin and aspirin-like drugs
•clopidogrel
•dipyridamole
•herbal products containing feverfew, garlic, ginger, ginkgo, or horse chestnut
•medicines that break up blood clots like alteplase, reteplase, streptokinase, and urokinase
•medicines that treat or prevent blood clots like warfarin, enoxaparin, dalteparin, tinzaparin, argatroban, bivalirudin, and lepirudin
•NSAIDs, medicines for pain and inflammation, like ibuprofen or naproxen
•ticlopidine
This list may not describe all possible interactions. Give your health care provider a list of all the medicines, herbs, non-prescription drugs, or dietary supplements you use. Also tell them if you smoke, drink alcohol, or use illegal drugs. Some items may interact with your medicine.
What should I watch for while using this medicine?
Your condition will be monitored carefully while you are receiving this medicine.
What side effects may I notice from receiving this medicine?
Side effects that you should report to your doctor or health care professional as soon as possible:
•allergic reactions like skin rash, itching or hives, swelling of the face, lips, or tongue
•breathing problems
•chest pain
•unusual bleeding or bruising
Side effects that usually do not require medical attention (report to your doctor or health care professional if they continue or are bothersome):
•back pain
•dizziness
•headache
•nausea
•stomach pain
This list may not describe all possible side effects. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Where should I keep my medicine?
This drug is given in a hospital or clinic and will not be stored at home.
Last updated: 7/1/2002
Important Disclaimer: The drug information provided here is for educational purposes only. It is intended to supplement, not substitute for, the diagnosis, treatment and advice of a medical professional. This drug information does not cover all possible uses, precautions, side effects and interactions. It should not be construed to indicate that this or any drug is safe for you. Consult your medical professional for guidance before using any prescription or over the counter drugs.
Oxford A-Z of Medicinal Drugs:
Top
abciximab
A monoclonal antibody that has antiplatelet activity and is used in patients undergoing balloon angioplasty and other forms of heart surgery. It may also be used in the treatment of patients with unstable angina. Abciximab is used only under specialist supervision, with careful monitoring of blood clotting; it is available as a solution for intravenous injection or infusion on prescription only.
Side effects:
include excessive bleeding, high blood pressure, nausea, vomiting, blood disorders, and a fast heart rate.
Precautions:
abciximab should not be used in people who have had a stroke within the previous two years or recent major surgery, or who have other risk factors for spontaneous bleeding, or by women who are pregnant or breastfeeding. It is also not recommended for patients with certain blood platelet disorders or severe kidney or liver disease.
Proprietary preparation:
ReoPro.
| abatacept, abacavir, Azarga | |
| acamprosate calcium, acarbose, acebutolol |
Wikipedia on Answers.com:
Top
Abciximab
| Monoclonal antibody | |
|---|---|
| Type | Fab fragment |
| Source | Chimeric (mouse/human) |
| Target | CD41 7E3 |
| Clinical data | |
| Trade names | Reopro |
| AHFS/Drugs.com | monograph |
| Pregnancy cat. | C (US) |
| Legal status | ? |
| Routes | IV |
| Pharmacokinetic data | |
| Half-life | <10 min–30 min |
| Identifiers | |
| CAS number | 143653-53-6  |
| ATC code | B01AC13 |
| DrugBank | DB00054 |
| UNII | X85G7936GV |
| KEGG | D02778 |
| ChEMBL | CHEMBL1201584  |
| Chemical data | |
| Formula | C2101H3229N551O673S15 |
| Mol. mass | 47455.4 g/mol |
 (what is this?) (verify) |
|
Abciximab (previously known as c7E3 Fab), a glycoprotein IIb/IIIa receptor antagonist manufactured by Centocor and distributed by Eli Lilly under the trade name ReoPro, is a platelet aggregation inhibitor mainly used during and after coronary artery procedures like angioplasty to prevent platelets from sticking together and causing thrombus (blood clot) formation within the coronary artery. It is a glycoprotein IIb/IIIa inhibitor.[1]
While Abciximab has a short plasma half-life, due to its strong affinity for its receptor on the platelets, it may occupy some receptors for weeks. In practice, platelet aggregation gradually returns to normal about 96 to 120 hours after discontinuation of the drug.[citation needed]
Abciximab is made from the Fab fragments of an immunoglobulin that targets the glycoprotein IIb/IIIa receptor on the platelet membrane.[2]
|
Contents
|
Indications for use
Abciximab is indicated for use in individuals undergoing percutaneous coronary intervention (angioplasty with or without stent placement). The use of abciximab in this setting is associated with a decreased incidence of ischemic complications due to the procedure[3] and a decreased need for repeated coronary artery revascularization in the first month following the procedure.[4] Research also shows that this drug can be of use for patients with diabetes and chronic renal insufficiency. It is not the appropriate drug of choice if a patient is scheduled for an emergency surgery (i.e., heart surgery) because bleeding time may take about 12 hours to normalize.
Pharmacokinetics
Abciximab has a plasma half-life of about ten minutes, with a second phase half-life of about 30 minutes. However, its effects on platelet function can be seen for up to 48 hours after the infusion has been terminated, and low levels of glycoprotein IIb/IIIa receptor blockade are present for up to 15 days after the infusion is terminated.
Side-effects
Many of the side effects of abciximab are due to its anti-platelet effects. This includes an increased risk of bleeding. The most common type of bleeding due to abciximab is gastrointestinal hemorrhage.
Thrombocytopenia is a rare but known serious risk. Abciximab-induced thrombocytopenia can typically be treated with transfusion of platelets. Abciximab induced thrombocytopenia can last for seven days after initial drug administration. Transfusing platelets is the only known treatment and may have limited effectiveness as the drug may also bind to the new platelets. Platelet counts, which should average 250,000-400,000, can effectively drop to zero[citation needed].
References
- ^ "Abciximab". Drugs.com. Archived from the original on 20 April 2010. http://www.drugs.com/cdi/abciximab.html. Retrieved 13 March 2010.
- ^ "International Nonproprietary Names for Pharmaceutiical Substances". WHO Drug Information 7 (4). 1993. http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list70.pdf.
- ^ "Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation.". The New England Journal of Medicine 330 (14): 956–61. 1994. doi:10.1056/NEJM199404073301402. PMID 8121459.
- ^ Tcheng, JE; Kandzari, DE; Grines, CL; Cox, DA; Effron, MB; Garcia, E; Griffin, JJ; Guagliumi, G et al (2003). "Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.". Circulation 108 (11): 1316–23. doi:10.1161/01.CIR.0000087601.45803.86. PMID 12939213.
External links
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
Post a question - any question - to the WikiAnswers community:
Copyrights:
Oxford A-Z of Medicinal Drugs
Market University Press. © 2000, 2003, 2010 An A-Z of Medicinal Drugs. All rights reserved.
Read more
